Biomerieux Shares Drop 8% Over the Week, Hindered by Downward Momentum

Weekly Performance Overview

Biomerieux ended the week down by 8%, with a closing price set at 104.60 euros. This performance starkly contrasts with its environment: the CAC 40 gained 0.19% over the same period, while the SBF 120 advanced by 0.13%. The discrepancy is thus evident. Throughout 2025 to date, the stock has suffered a decline of 4.82%, indicative of a bearish trend that has been established for several months. The stock now trades well below its moving averages: the 50-day average stands at 108.18 euros, while the 200-day average is at 115.40 euros, creating a deteriorated chart configuration. Analysts have set a three-month price target of 123.74 euros, suggesting a potential upside of 17.29%, even though this hope is not enough to stem the current sales. The estimated yield for 2026 stands at 1.03%, with a dividend expected to be 1.16 euros per share.

Technical Analysis Insights

Technical analysis offers no immediate signs of stabilization. The Relative Strength Index (RSI) stands at 35, indicating a marked selling dynamic, while the MACD shows a line at -0.29, confirming the weakness of momentum. The stock is now fluctuating between its support levels at 104.20 euros and resistance at 114.80 euros, in a narrow range that limits volatility, measured at 6.23% over a month. The Bollinger Bands, positioned between 105.05 and 114.89 euros, enclose the price near their lower limit, reflecting bearish pressure. The beta ratio of -0.18 suggests a reverse sensitivity to the market, an atypical trait that may reflect specific sector dynamics of the group or a specific portfolio composition. This technical setup calls for increased vigilance, especially if the stock were to test its current supports.